Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aquestive Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Aquestive Therapeutics, Inc.

AQST

Aquestive Therapeutics, Inc.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company specializing in innovative drug delivery technologies, notably its proprietary PharmFilm oral film platform. It develops and manufactures complex molecule-based therapies, including Libervant® buccal film for epilepsy and Anaphylm™ sublingual film for anaphylaxis. Aquestive supplies licensed products globally and focuses on improving patient compliance through non-invasive, fast-acting alternatives to traditional injectable or device-dependent treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aquestive Therapeutics, Inc.

1
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 66% Revenue Growth and Improved Net Loss in Latest Quarter

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 23% Revenue Decline, Focuses on Anaphylm Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports Q3 2025 Revenue Decline and Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 50% Revenue Decline in Q2 2025, Net Loss of $36.5 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 28% Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 14% Revenue Growth to $57.6 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aquestive Therapeutics, Inc. Aquestive Therapeutics Reports 4% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments